Peer-reviewedCC BY-NC-NDJournal of thoracic disease
Pirfenidone in bronchiolitis obliterans syndrome after lung transplantation: two negative trials, one clearer path forward.
- 1Division of Pulmonary, Allergy, and Critical Care Medicine, Duke University School of Medicine, Durham, NC, USA.
Related
- Pirfenidone fails to improve outcomes in progressive bronchiolitis obliterans syndrome post-lung transplant.
- Exercise capacity and handgrip strength following dumbbell-assisted diaphragmatic breathing training in patients with bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation: a prospective single-arm study
- Bronchiolitis Obliterans Syndrome After Allogeneic HSCT: Clinical Characteristics and Survival Outcomes in a Single Center Cohort
- Development of a clinical and bronchoalveolar lavage fluid biomarker model for predicting post-infectious bronchiolitis obliterans in hospitalized children
- Membranous obliterans bronchitis after hematopoietic stem cell transplantation: case report.
BibTeX
@article{srivali2026pirfenidone,
title = {{Pirfenidone in bronchiolitis obliterans syndrome after lung transplantation: two negative trials, one clearer path forward.}},
author = {Narat Srivali},
journal = {Journal of thoracic disease},
year = {2026},
month = oct,
doi = {10.21037/jtd-2026-2412},
url = {https://europepmc.org/article/MED/42996960},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Pirfenidone in bronchiolitis obliterans syndrome after lung transplantation: two negative trials, one clearer path forward.
AU - Narat Srivali
PY - 2026
DA - 2026/10/21
JO - Journal of thoracic disease
DO - 10.21037/jtd-2026-2412
UR - https://europepmc.org/article/MED/42996960
SN - 2072-1439
SN - 2077-6624
ER -